Genmab gains its first milestone payment from Serono  

2006.03.07
Danish-American biotech firm Genmab has gained its first milestone payment from a development and commercialisation agreement between Genmab and Serono

Danish-American biotech firm Genmab has gained its first milestone payment from a development and commercialisation agreement between Genmab and Serono, a biotech company headquartered in Geneva, Switzerland. Genmab has delivered a HuMax-TAC cell line to Serono which can be used to manufacture HuMax-TAC for clinical trials. The milestone triggers a USD 1 m payment to Genmab.

HuMax-TAC is a fully human monoclonal antibody which might have therapeutic potential for the treatment of T-cell mediated diseases such as autoimmune disorders, skin disorders and transplant rejection. HuMax-TAC is currently in preclinical trials. In May 2005, Genmab and Serono entered an agreement under which Genmab granted Serono exclusive worldwide rights to develop and commercialise Genmab's HuMax-TAC. The news was reported by Biotech Denmark and in a press release from Genmab.

Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions. Genmab currently has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US.

Link > Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×